key: cord-0844285-666snka0 authors: Joly, Bérangère S.; Darmon, Michael; Dekimpe, Charlotte; Dupont, Thibault; Dumas, Guillaume; Yvin, Elise; Beranger, Nicolas; Vanhoorelbeke, Karen; Azoulay, Elie; Veyradier, Agnès title: Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID‐19 patients date: 2021-07-27 journal: J Thromb Haemost DOI: 10.1111/jth.15445 sha: 075df49197b2067a284b1dae09088c112001d526 doc_id: 844285 cord_uid: 666snka0 BACKGROUND: Critically ill patients with coronavirus disease 2019 (COVID‐19) are prone to developing macrothrombosis and microthrombosis. COVID‐19 has been reported to be rarely associated with thrombotic microangiopathies. A disintegrin and metalloprotease with thrombospondin type I repeats, member 13 (ADAMTS13) severe deficiency, the hallmark of thrombotic thrombocytopenic purpura (TTP), induces the formation of platelet, unusually large von Willebrand factor (VWF) multimer microthrombi. In immune‐mediated TTP, ADAMTS13 adopts specifically an open conformation. The VWF/ADAMTS13 couple may contribute to the microthrombi formation in pulmonary alveolar capillaries in COVID‐19. OBJECTIVE: To investigate clinical features, hemostatic laboratory parameters, VWF/ADAMTS13 axis, and ADAMTS13 conformation in critically ill COVID‐19 patients at admission. METHODS: Fifty three critically ill COVID‐19 patients were enrolled between March 18 and May 9 2020 in a monocentric hospital. RESULTS: The median age was 59 years and the male‐to‐female ratio was 2.8/1. We reported seven pulmonary embolisms and 15 deaths. Biological investigations showed increased fibrinogen and factor V levels, and strongly increased D‐dimers correlated with mortality. No patient presented severe thrombocytopenia nor microangiopathic hemolytic anemia. An imbalance between high VWF antigen levels and normal or slightly decreased ADAMTS13 activity levels (strongly elevated VWF/ADAMTS13 ratio) was correlated with mortality. Three patients had a partial quantitative deficiency in ADAMTS13. We also reported a closed conformation of ADAMTS13 in all patients, reinforcing the specificity of an open conformation of ADAMTS13 as a hallmark of TTP. CONCLUSION: We suggest that slightly decreased or normal ADAMTS13 activity and highly elevated VWF are rather biomarkers reflecting both the strong inflammation and the endothelial damage rather than drivers of the thrombotic process of COVID‐19. ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I repeats, member 13) is the specific cleaving protease for von Willebrand factor (VWF), a multimeric glycoprotein released in blood from endothelial cells and that mediates platelet adhesion and aggregation. 1 Under physiological conditions, ADAMTS13 regulates the size of VWF multimers to prevent platelet-rich thrombi formation in the blood microvessels and it circulates in a closed conformation through a CUB-spacer (complement component Clr/Cls, Uegf, and bone morphogenic protein 1) domains interaction, which is temporarily disrupted upon binding to VWF. 2 The pathologic development of autoantibodies to ADAMTS13 induces a severe ADAMTS13 deficiency (activity <10 IU/dl), leading to the accumulation of ultralarge VWF multimers and subsequent systemic microvascular thrombosis that causes a specific thrombotic microangiopathy (TMA) named immune-mediated thrombotic thrombocytopenic purpura (iTTP). Moreover, specifically in acute iTTP, ADAMTS13 adopts a sustained open conformation, likely mediated by ADAMTS13 autoantibodies. 2, 3 In addition, bacterial and viral infections are triggers of TTP but their role on ADAMTS13 conformation is not known yet. Interestingly, a high frequency of both macrovascular and microvascular thrombosis affecting lungs, kidneys, heart, and potentially complicated by multiorgan failure has been reported in prospective cohort studies led in critically ill patients with coronavirus disease 2019 (COVID- 19) . [4] [5] [6] This novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to angiotensinconverting enzyme 2, highly expressed in lung alveolar cells but also in the vascular endothelium. 6 The aggression of the endothelial host cells by SARS-CoV-2 explains both the endotheliopathy and the thromboinflammation processes supporting thrombotic microvascular events. 6 Since 2020, to further understand the pathophysiology for SARS-CoV-2-related microthrombosis, several studies have focused on the VWF/ADAMTS13 axis in COVID-19 patients admitted on general wards and/or intensive care units (ICUs). [7] [8] [9] [10] [11] [12] In summary, most results converge to an imbalance between VWF and ADAMTS13 showing markedly increased VWF antigen levels and VWF collagen-binding capacity but normal or slightly decreased ADAMTS13 activity, [7] [8] [9] [10] [11] [12] [13] [14] resulting in the formation of large VWF multimers, [15] [16] [17] [18] with the latter biomarkers sometimes correlating with mortality. [9] [10] [11] [12] 15, 17 This VWF/ADAMTS13 imbalance may support the concept of a secondary TMA-like syndrome potentially present in some critically ill COVID-19 patients and contributing to the microthrombi formation in pulmonary alveolar capillaries. 8, 11, 15, 19 Surprisingly, however, ~20 TTP cases likely triggered by a SARS-CoV-2 infection were recently reported. [20] [21] [22] [23] [24] [25] Also, the link between a TMA process and the COVID-19-associated microthrombosis may be supported by the clinical improvement and the reduction of circulating thromboinflammatory markers (i.e., the VWF/ADAMTS13 ratio) induced by plasma exchange undertaken in some critically ill COVID-19 patients. 15, 26 One ex vivo study suggested that purified recombinant ADAMTS13 should be considered as a potential therapy for COVID-19 patients. 16 To date however, no study has investigated ADAMTS13 conformation in COVID-19 patients, although infectious triggers are candidates to explain the initial disruption of the interaction between self-domains of ADAMTS13 leading to its switch from a folded to an open conformation. In the current study, our major aim was thus to investigate hemostatic laboratory parameters and plasmatic ADAMTS13 features including ADAMTS13 conformation in critically ill COVID-19 patients at ICU admission. The protocol was approved by the local institutional ethical committee. All consecutive patients admitted for acute respiratory distress syndrome (ARDS) by SARS-CoV-2 in the ICU of Saint-Louis hospital Conclusion: We suggest that slightly decreased or normal ADAMTS13 activity and highly elevated VWF are rather biomarkers reflecting both the strong inflammation and the endothelial damage rather than drivers of the thrombotic process of COVID-19. ADAMTS13, ADAMTS13 conformation, COVID-19, thrombotic microangiopathy, von Willebrand factor Essentials • High frequency of macrovascular and microvascular thromboembolic events is reported in COVID-19. • von Willebrand factor/ADAMTS13 ratio is strongly elevated and correlated to mortality in COVID19. • ADAMTS13 conformation is closed in severe COVID-19 in contrast to immune-mediated TTP. • VWF and ADAMTS13 are biomarkers of endotheliopathy in COVID-19. (AP-HP, Paris, France) between March 18 and May 9, 2020, were enrolled. 27 Real-time quantitative PCR assay for SARS-CoV-2 RNA on nasopharyngeal swab specimens was positive in all patients. Clinical data and outcome were analyzed from medical records. The following biological parameters were measured at admission: hemoglobin, platelet count, lactate dehydrogenase (LDH), fibrinogen, D-dimers, and factor V in the context of care. Characteristics and outcome of the 53 patients enrolled are shown in between severe COVID-19-related microthrombosis and secondary TMA-like syndrome enhanced by partial consumption and/or inhibition of ADAMTS13 by inflammatory cytokines as IL-6, in line with a process similar to that observed in sepsis. 1, 6 In COVID-19, a phenomenon of thrombotic pulmonary capillaritis supporting ARDS could be partially explained by the unbalance between VWF and ADAMTS13 and play a crucial role in short-term prognosis. [6] [7] [8] [9] [10] [11] [12] Altogether, our results also reinforce the specificity of an open conformation of ADAMTS13 as a hallmark of iTTP. 2, 3 In conclusion, COVID-19-associated TMA is likely mostly restricted to the pulmonary microcirculation. This study suggests that normal or slightly low ADAMTS13 activity and highly elevated VWF are rather biomarkers reflecting strong inflammation and endothelial damage rather than drivers of the thrombotic process reported in COVID-19. Further studies are definitely needed to consider the VWF/ADAMTS13 axis as a rational therapeutic option in severe COVID-19. This work was partly funded by KU Leuven grant COVID19-Thrombosis in COVID19. We thank Sandrine Benghezal, Sophie Capdenat, Adeline Delton, and Sylvaine Savigny for expert technical assistance. None of the authors has any conflict of interest to declare. Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19 Microvascular dysfunction in COVID-19: the MYSTIC study ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19 Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink The ADAMTS13-von Willebrand factor axis in COVID-19 patients ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy Circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality Von Willebrand factor collagenbinding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance von Willebrand factor / ADAMTS13 axis and venous thromboembolism in moderate-tosevere COVID-19 patients von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019 Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19 Low ADAMTS13 activity correlates with increased mortality in COVID-19 patients ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans Dramatic presentation of acquired thrombotic thrombocytopenic purpura associated with COVID-19 Thrombotic thrombocytopenic purpura as the initial presentation of COVID-19 Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19 Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: report of a case COVID 19 infection associated with thrombotic thrombocytopenic purpura COVID-19 associated thrombotic thrombocytopenic purpura (TTP); a case series and mini-review Plasma exchange for COVID-19 thrombo-inflammatory disease Clinical phenotypes of critically ill COVID-19 patients Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation No evidence for classic thrombotic microangiopathy in COVID-19 COVID-19 patients